- Home
- GGT vs CGEN Comparison
GGT vs CGEN Comparison
Compare GGT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGT
- CGEN
- Stock Information
- Founded
- GGT 1994
- CGEN 1993
- Country
- GGT United States
- CGEN Israel
- Employees
- GGT N/A
- CGEN N/A
- Industry
- GGT Trusts Except Educational Religious and Charitable
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GGT Finance
- CGEN Health Care
- Exchange
- GGT Nasdaq
- CGEN Nasdaq
- Market Cap
- GGT N/A
- CGEN 149.6M
- IPO Year
- GGT N/A
- CGEN 2000
- Fundamental
- Price
- GGT $4.64
- CGEN $1.41
- Analyst Decision
- GGT
- CGEN Strong Buy
- Analyst Count
- GGT 0
- CGEN 1
- Target Price
- GGT N/A
- CGEN $4.00
- AVG Volume (30 Days)
- GGT 59.7K
- CGEN 264.2K
- Earning Date
- GGT 01-01-0001
- CGEN 05-19-2025
- Dividend Yield
- GGT 15.56%
- CGEN N/A
- EPS Growth
- GGT N/A
- CGEN N/A
- EPS
- GGT 0.83
- CGEN N/A
- Revenue
- GGT N/A
- CGEN $27,864,000.00
- Revenue This Year
- GGT N/A
- CGEN $11.81
- Revenue Next Year
- GGT N/A
- CGEN $28.37
- P/E Ratio
- GGT $6.90
- CGEN N/A
- Revenue Growth
- GGT N/A
- CGEN N/A
- 52 Week Low
- GGT $4.32
- CGEN $1.35
- 52 Week High
- GGT $7.00
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- GGT 37.80
- CGEN 29.77
- Support Level
- GGT $4.56
- CGEN $1.50
- Resistance Level
- GGT $4.94
- CGEN $1.65
- Average True Range (ATR)
- GGT 0.10
- CGEN 0.06
- MACD
- GGT -0.01
- CGEN -0.00
- Stochastic Oscillator
- GGT 21.05
- CGEN 3.45
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.